cas 220127-57-1, Imatinib mesylate | Articles data

Articles about 220127-57-1Total 54 be found

Article title
Article abstract
Author
Journal number and time
Download

A PROCESS FOR PREPARATION OF IMATINIB BY USING VILSMEIER REAGENT
The present invention relates to a process of preparation of Imatinib, wherein said process comprises one or more steps of converting benzoic acid intermediate (formula 8) into Imatinib in presence of Vilsmeier reagent preferably under basic condition. Vilsmeier reagent in the present invention is prepared by reaction of chlorinating agent and catalyst. In a preferred embodiment Chlorinating agent is thionyl chloride and catalyst is dimethyl formamide.
-
(2021/07/17)

Synthesis method of imatinib and imatinib mesylate
The invention relates to a synthesis method of imatinib and imatinib mesylate. The method comprises the following steps: condensing 3-acetylpyridine and N,N-dimethylformamide dimethyl acetal which aretaken as initial raw materials to obtain 3-dimethylamino-1-(3-pyridyl)-2-propen-1-one, then reacting with 2-methyl-5-nitrophenylguanidine nitrate to form a pyrimidine ring, performing nitro reductionto obtain N-(5-amino-2-methylphenyl)-4-(3-pyridyl)-2-pyrimidinamine, amidating the N-(5-amino-2-methylphenyl)-4-(3-pyridyl)-2-pyrimidinamine and 4-(chloromethyl)benzoyl chloride, performing affinitysubstitution with 1-methylpiperazine to obtain imatinib, and salifying the imatinib and methanesulfonic acid. The products obtained by the method have the advantages of few impurities, simplicity in post-treatment, high total yield, greenness, environmental protection and safety, and is suitable for a production process for large-scale industrial production of imatinib mesylate.
-
(2020/05/02)

Preparation method of imatinib mesylate
The invention discloses a preparation method of imatinib mesylate. The method comprises the following steps: chlorinating imatinib acid[4-(4-methylpiperazine-1-ylmethyl)benzoic acid dihydrochloride] with thionyl chloride to generate an imatinib mesylate intermediate I; condensing the imatinib mesylate intermediate I with imatinib amine [N-(5-amino-2-methylphenyl)-4-(3-pyridyl)-2-pyrimidinamine] toobtain an imatinib mesylate intermediate II, and finally salifying the imatinib mesylate intermediate II with methanesulfonic acid to obtain imatinib mesylate. According to the invention, the raw materials imatinib acid and imatinib amine used in the method are common medical intermediates, other raw materials and reagents used in the process are convenient and easy to obtain, the reaction process and post-treatment operation are simple and convenient, the yield is high, and the production cost is effectively reduced through process optimization.
-
(2020/12/05)

IMATINIB mesylate α crystal preparation method
The invention relates to the field of drug synthesis and discloses a preparation method of an imatinib mesylate alpha crystal form. In the preparation method, imatinib alkali is mixed with chloroform, and the mixture reacts with the methanesulfonic acid-c
-
Paragraph 0028; 0029; 0031; 0033

(2018/04/20)

Purification method of imatinib
The invention relates to a purification method of imatinib. The method has the characteristics of simple technique, high safety, environment friendliness, low cost and favorable repeatability, and can implement industrialized large-scale production. By using the method, the content of the genotoxic impurity N-(5-amino-2-methylphenyl)-4-(3-pyridyl)-2-aminopyrimidine in the imatinib can be lowered to 2ppm or below according to the pharmacopoeia requirement, and the product purity is up to 99.8% or above.
-
Paragraph 0090; 0091; 0092; 0093

(2017/10/28)

Preparation method of imatinib mesylate
The invention discloses a preparation method of imatinib mesylate. The method specifically comprises steps as follows: 4-[(4-methylpiperazin-1-yl)methyl]benzoic acid dihydrochloride type compounds II are taken as a starting material, sodium carbonate and N, N'-carbonyl diimidazole are added, acyl imidazole with higher activity is obtained, separation is not required, N-(5-amino-2-methylphenyl)-4-(3-pyridyl)-2-pyrimidineamine type compounds IV and a catalyst imidazole hydrochloride are directly added, the mixture reacts, free alkali imatinib is obtained, methylsulfonic acid is added for salt formation, and imatinib mesylate in an alpha crystal form is obtained after recrystallization. The preparation method has the advantages of being mild in reaction condition, lower in cost, simple and convenient to operate, high in yield, good in reaction reproducibility, economical, environment-friendly and suitable for industrial production and producing fewer side reactions.
-
(2017/07/20)

An imatinib mesylate crystal form suitable for officinal uses and a preparing method thereof
The invention relates to 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-phenyl]phenylamine mesylate shown as a formula (1), namely an imatinib mesylate non-needle alpha crystal form, and a preparing method thereof.
-
Paragraph 0027

(2017/06/20)

Preparation method of non-acicular alpha crystal form imatinib mesylate
The invention discloses a preparation method of non-acicular alpha crystal form imatinib mesylate. The method comprises the following steps: (1) performing reduction reaction by taking N-(2-methyl-5-nitrophenyl)-4-(3-pyridyl)-2-aminopyrimidine as a raw material, methanol as a solvent, KBH4 as a reducing agent and ZrCl4 as a catalyst to obtain N-(5-amino-2-methylphenyl)-4-(3-pyridyl)-2-pyrimidineamine; (2) after activating 4-[(4-methylpiperazin-1-yl)methyl]benzoic acid dihydrochloride hemihydrates by using CBMIT, performing acylation reaction with equimolar N-(5-amino-2-methylphenyl)-4-(3-pyridyl)-2-pyrimidineamine by taking DMF as a solvent to obtain imatinib alkali; and (3) suspending the imatinib alkali in isopropanol, adding an acetone solution of methylsulfonic acid, heating for reflux reaction, cooling for crystallization, filtering, and drying to obtain a non-acicular imatinib mesylate alpha crystal form. The preparation method disclosed by the invention has the advantages of being simple in operation, small in environmental harm, safe, reliable, relatively short in reaction time, good in product quality, high in yield and the like, and is suitable for industrial production.
-
(2016/12/01)

Methanesulfonic acid iraq Ma Ti nepalese crystalline α and its preparation of pharmaceutical compositions
The invention belongs to the technical field of medicine, relates to preparation of an imatinib mesylate alpha crystal and a pharmaceutical composition thereof, and provides a preparation method of the imatinib mesylate alpha crystal. The method provided by the invention is short in reaction step, simple to operate, small in toxicity of a used solvent, small in environmental pollution, high in total yield, and low in cost. The prepared product is high in purity and applicable to large-scale industrial operation. The crystalline of the prepared imatinib mesylate alpha crystal is over 60%. The pharmaceutical composition containing the imatinib mesylate alpha crystal provided by the invention has the advantages that the defects of poor liquidity, unstable thermodynamics and strong hygroscopicity of the imatinib mesylate alpha crystal are overcome, and the prepared composition is even in content and strong in stability after long-term placement.
-
(2017/01/12)

A method of manufacturing a crystal type α pridinol Imanitib
The present invention provides a method for preparing the alpha-crystalline form of imatinib mesylate. The method of the present invention may involve using a mixed solvent as a reaction solvent to significantly reduce the content of isopropyl alcohol remaining in the alpha-crystalline form of imatinib mesylate ultimately obtained.
-
(2018/10/19)

PROCESS FOR PREPARING IMATINIB AND IMATINIB MESYLATE NON-NEEDLE SHAPED α2 FORM
The present invention relates to an efficient process and industrially feasible for the preparation of imatinib and imatinib mesylate non-needle shaped α2 form with high purity, without requiring purification by recrystallization or column chromatography. The process of the present invention is easy, fast and economical, wherein the imatinib mesylate is obtained with high yield and purity.
-
Page/Page column 8; 25; 26

(2016/01/01)

Imatinib analogs as potential agents for PET imaging of Bcr-Abl and c-KIT expression at a kinase level
We synthesized two series of imatinib mesylate (STI-571) analogs to develop a Bcr-Abl and c-KIT receptor-specific labeling agent for positron emission tomography (PET) imaging to measure Bcr-Abl and c-KIT expression levels in a mouse model. The methods of molecular modeling, synthesis of STI-571 and its analogs, in vitro kinase assays, and radiolabeling are described. Molecular modeling revealed that these analogs bind the same Bcr-Abl and c-KIT binding sites as those bound by STI-571. The analogs potently inhibit the tyrosine kinase activity of Bcr-Abl and c-KIT, similarly to STI-571. [ 18F]-labeled STI-571 was prepared with high specific activity (75 GBq/μmol) by nucleophilic displacement and an average radiochemical yield of 12%. [131I]-labeled STI-571 was prepared with high purity (>95%) and an average radiochemical yield of 23%. The uptake rates of [ 18F]-STI-571 in K562 cells expressing Abl and in U87WT cells overexpressing c-KIT were significantly higher than those in the U87 cell and could be inhibited by STI-71 (confirming the specificity of uptake). PET scans of K562 and U87WT tumor-bearing mice with [18F]-STI-571 as a contrast agent showed visible tumor uptake and tumor-to-non-target contrast.
Peng, Zhenghong,Maxwell, David S.,Sun, Duoli,Bhanu Prasad, Basvoju A.,Pal, Ashutosh,Wang, Shimei,Balatoni, Julius,Ghosh, Pradip,Lim, Seok T.,Volgin, Andrei,Shavrin, Aleksander,Alauddin, Mian M.,Gelovani, Juri G.,Bornmann, William G.
p. 623 - 632
(2014/01/17)

NOVEL COMPOUNDS, THEIR PREPARATION AND THEIR USES
Novel compounds and their synthesis are described. Methods for using these compounds in the prevention or treatment of cancer, a bacterial infection or a viral infection in a subject are also described.
-
(2014/04/18)

PROCESS FOR THE PREPARATION OF AMORPHOUS IMATINIB MESYLATE
The field of the invention relates to a process for the preparation of amorphous imatinib mesylate. In particular, the invention relates to a process for the preparation of stable amorphous imatinib mesylate. More particularly, the invention relates to ph
-
Paragraph 0084

(2014/05/08)

CRYSTALLINE IMATINIB MESYLATE PROCESS
The present invention relates to a process for preparation of crystalline non-needle shaped Form-SA of Imatinib mesylate (I).(Formula I) (I) The invention also relates to crystalline Form-SA obtained by the process of the present invention, the said Form-
-
Page/Page column 11; 12

(2015/01/09)

Preparation Method of alpha-imatinib Mesylate
Disclosed is a preparation method of α-imatinib mesylate. The reaction temperature of the method is low and the yield of the crystal is improved. Furthermore, the method is applicable to the industrial production.
-
Paragraph 0031

(2013/09/26)

AN IMPROVED PROCESS FOR THE PREPARATION OF ALPHA FORM OF IMATINIB MESYLATE
An improved process, which is simple, convenient, economical and industrially viable, for the preparation of stable, free flowing, non-hygroscopic crystalline alpha form of Imatinib mesylate, free from the beta form. The process comprises a) providing a c
-
Page/Page column 8; 9

(2013/09/26)

Imatinib mesylate preparation procedure
The present invention concerns a procedure for the preparation of Imatinib mesylate having a content of residual solvents in compliance with ICH guidelines. In particular, the invention concerns a procedure for the preparation of Imatinib mesylate of form
-
Paragraph 0032; 0033; 0034

(2013/03/26)

IMATINIB MESYLATE PREPARATION PROCEDURE
Methods for making Imatinib mesylate of formula (I): having low levels of organic solvent are provided. Also provided are alpha and beta forms of Imatinib mesylate and methods for treating conditions such as chronic myelogenous leukaemia by administering
-
Paragraph 0032; 0033; 0034

(2013/03/26)

Polymorphs of imatinib
This invention relates to novel, stable, highly soluble M, Y, B, P polymorphs of imatinib mesylate and process for preparation thereof and pharmaceutical compositions comprising imatinib mesylate.
-
Paragraph 0130-0131

(2013/06/28)

IMPROVED PROCESS FOR PREPARATION OF IMATINIB AND ITS MESYLATE SALT
Disclosed is a process for the preparation of imatinib of formula (I), or its mesylate salt with controlled level of genotoxic impurity of formula (II), a key intermediate for imatinib.
-
(2012/10/18)

STABLE α-CRYSTAL FORM OF IMATINIB MESYLATE AND PREPARING PROCESS THEREOF
A stable, free flowing and non -hygroscopic α-crystalline form of 4-(4-methyl piperazin-1-yl methyl)-N-[4-methyl-3- (4-pyridin-3-yl)pyrimidin-2-yl amino)phenyl]-benzamide monomethanesulfonate (imatinib mesylate) is disclosed. A process for preparing the a
-
Example 2

(2012/02/13)

PROCESS FOR THE PREPARATION OF IMATINIB MESYLATE
The present application relates to process for the preparation of imatinib mesylate. This application also relates to the processes for preparation of alpha crystalline form of imatinib mesylate.
-
Page/Page column 31

(2012/02/13)

IMATINIB DICHLOROACETATE AND ANTI-CANCER AGENT COMPRISING THE SAME
The present invention relates to imatinib dichloroacetate and an anti-cancer agent comprising the same. The imatinib dichloroacetate of the present invention can inhibit tyrosine kinase as well as induce cancer cells to kill themselves via apoptosis, ther
-
Page/Page column 4

(2012/12/13)

PROCESS FOR THE PREPARATION OF ALPHA FORM OF IMATINIB MESYLATE
The present invention provides an improved process for the preparation of alpha form of imatinib mesylate with (long needle) and α- crystal form (small needle) in a consistent manner and novel alpha crystal forms of imatinib mesylate. The present invention in particular provides a reproducible and efficient process. In particular the present invention provides a efficient process which gives higher yields and consistent results.
-
Page/Page column 13

(2011/09/15)

IMATINIB MESYLATE POLYMORPHS
The present application relates to crystalline forms of imatinib mesylate and process for preparation thereof.
-
Page/Page column 18-19

(2011/09/15)

IMATINIB MESYLATE POLYMORPHS GENERATED BY CRYSTALLIZATION IN AQUEOUS INORGANIC SALT SOLUTIONS
The solution relates to a method of preparation of an imatinib mesylate polymorph as an AP1 form suitable for dosage forms. Formation of new polymorphs of tyrosine kinase inhibitors proceeds depending on the conditions, said method consisting of the following steps: a) preparation of imatinib mesylate by reaction of the imalinib base and methanesulfonic acid in aqueous environment or in a water-organic solvent mixture, with optional addition of an organic solvent; b) addition of an inorganic salt in an aqueous solution, controlling the pH and ionic strength of the solution; c) crystallization process at controlled temperature. The solution also relates to the crystalline form of imatinib mesylate polymorph and use thereof. Two new polymorphous forms of Imatinib mesylate are accessible through this method, these forms are named polymorph Z1 and Z2 . Z1 is characterized by peaks in the XRPD at 5,3; 7,5; 10,0; 10,6; 14,1; 15,0 and 16;6°. Z2 is characterized by peaks in the XRPD at 5,5; 10,6; 10,9; 14.9; 17,0 and 21,9°.
-
Page/Page column 18

(2011/04/14)

PROCESS FOR THE PREPARATION OF HIGHLY PURE CRYSTALLINE IMATINIB BASE
A process for the preparation of highly pure crystalline imatinib base form- N of Formula (I) is disclosed. Imatinib base of this invention is suitable for conversion to pharmaceutically acceptable salts.
-
Page/Page column 13

(2011/10/10)

NEW POLYMORPHIC FORM OF IMATINIB BASE AND PREPARATION OF SALTS THEREOF
The invention relates to a process for the manufacture of new polymorph of imatinib base, the preparation of mesylate salt thereof and their inclusion into pharmaceutical compositions which have an improved stability and purity, as well as processes for their preparation.
-
Page/Page column 19

(2012/01/06)

HIGHLY PURE IMATINIB OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF
Provided herein are impurities of imatinib, N-acetylpiperazine, N-acetylamino, N- chloromethylamino, formamide, 4-methylbenzamide and '2.24 RRt' impurities, and processes for the preparation and isolation thereof. Provided further herein is a highly pure imatinib or a pharmaceutically acceptable salt thereof substantially free of at least one, or two, or more, of the N-acetylpiperazine, N-acetylamino, N-chloromethylamino, formamide, 4-methylbenzamide, and '2.24 RRt' impurities, processes for the preparation, and pharmaceutical compositions comprising highly pure imatinib or a pharmaceutically acceptable salt thereof substantially free of impurities. Disclosed also herein is a process for preparing substantially pure α-form of imatinib mesylate.
-
(2011/09/14)

PROCESSES FOR PREPARING IMATINIB AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF
The processes for preparing imatinib and its pharmaceutically acceptable salts, specifically imatinib mesylate, are disclosed.
-
(2011/04/25)

PROCESS FOR PREPARATION OF POLYMORPHIC FORM α AND NEW POLYMORPHIC FORM OF IMATINIB MESYLATE ISOLATED IN THAT PROCESS
In the present invention, the process of preparation of imatinib mesylate polymorphic form α, in the reaction of equimolar amounts of imatinib base and methanesulfonic acid in the mixture of isopropyl alcohol and diisopropyl ether or in methylene dichlori
-
Page/Page column 11-12

(2011/10/03)

IMATINIB DICHLOROACETATE AND ANTI-CANCER AGENT COMPRISING THE SAME
The present invention relates to imatinib dichloroacetate and an anti-cancer agent comprising the same. The imatinib dichloroacetate of the present invention can inhibit tyrosine kinase as well as induce cancer cells to kill themselves via apoptosis, ther
-
Page/Page column 9

(2011/07/30)

PROCESS FOR PREPARATION OF STABLE IMATINTB MESYLATE ALPHA FORM
The present invention provides a process for preparation of stable, free flowing, non-hygroscopic crystalline alpha form of Imatinib mesylate. The present invention also provides a pharmaceutical composition using the stable, free flowing, non hygroscopic
-
Page/Page column 11-12

(2012/01/06)

SUBSTANTIALLY PURE IMATINIB OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF
Provided herein are impurities of imatinib, N-(2-Methyl-5-methylamino-phenyl)-N- (4-pyridin-3-yl-pyrimidin-2-yl)-formamide (formamide impurity) and 4-[4-(Imidazole-1- carbonyl)-piperazin-1 -ylmethyl]-N-[4-methyl-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-phenyl]-benzamide (carbonylimidazole impurity), and processes for the preparation and isolation thereof. Provided further herein is a highly pure imatinib or a pharmaceutically acceptable salt thereof substantially free of formamide and carbonylimidazole impurities, processes for the preparation thereof, and pharmaceutical compositions comprising highly pure imatinib or a pharmaceutically acceptable salt thereof substantially free of impurities. Disclosed also herein is a process for preparing substantially pure α-form of imatinib mesylate.
-
Page/Page column 24; 25

(2010/12/18)

SUBSTANTIALLY PURE IMATINIB OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF
Provided herein are impurities of imatinib, N-(2-Methyl-5-methylamino-phenyl)-N-(4-pyridin-3-yl-pyrimidin-2-yl)-formamide (formamide impurity) and 4-[4-(Imidazole-1-carbonyl)-piperazin-1-ylmethyl]-N-[4-methyl-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-phenyl]-benzamide (carbonylimidazole impurity), and processes for the preparation and isolation thereof. Provided further herein is a highly pure imatinib or a pharmaceutically acceptable salt thereof substantially free of formamide and carbonylimidazole impurities, processes for the preparation thereof, and pharmaceutical compositions comprising highly pure imatinib or a pharmaceutically acceptable salt thereof substantially free of impurities. Disclosed also herein is a process for preparing substantially pure α-form of imatinib mesylate.
-
Page/Page column 10

(2011/01/05)

A PROCESS FOR THE PREPARATION OF IMATINIB
A process for the preparation of Imatinib according to the invention consists in converting the 2-methyl-5-halogenoaniline of the Formula 2 into the salt of the 2-methyl-5- halogenophenylguanidine of the Formula 3, which is then condensed with the 3-diaIkylamino- ]-(pyridin-3-yI)prop-2-en-l-one of the Formula 4 to yield the N-(2-methyl-5- halogenophenyl)-4-(pyridin-3-yl)-pyrimidin-2-ylamine of the Formula 5, which is then reacted with 4-(4-methylpiperazin-l-ylmethyl)benzamide of the Formula 6, and the obtained Imatinib is optionally converted into its addition salt.
-
Page/Page column 7-8

(2010/04/03)

Anhydrous Amorphous Imatinib Mesylate
Described is a highly stable amorphous form of imatinib mesylate having a water content of less than 0.5 percent by weight, based on the total weight of the amorphous imatinib mesylate, (anhydrous amorphous imatinib mesylate), a process for preparation thereof, and pharmaceutical compositions.
-
Page/Page column 5

(2009/07/25)

Polymorphic forms of imatinib mesylate and processes for preparation of novel crystalline forms as well as amorphous and form alpha
Solvates and crystalline forms of imatinib mesylate are described. Further, methods for preparing such solvates and crystalline forms of imatinib mesylate are described.
-
Page/Page column 20

(2009/10/30)

Processes for the preparation of crystalline form beta of imatinib mesylate
Provided is a process for the preparation of crystalline form β of Imatinib mesylate.
-
Page/Page column 3

(2009/01/24)

ANHYDROUS AMORPHOUS FORM OF IMATINIB MESYLATE
The present invention relates to an anhydrous amorphous form of Imatinib mesylate and a process for preparation thereof.
-
Page/Page column 6

(2009/12/28)

PREPARATION OF IMATINIB MESYLATE
Processes for preparing a non-hygroscopic and stable crystalline alpha-form imatinib mesylate.
-
Page 10

(2010/01/07)

STABLE AMORPHOUS IMATINIB MESYLATE AND PRODUCTION PROCESS THEREFOR
Provided herein is a spray dried stable amorphous imatinib mesylate as a free-flowing solid and process for producing the amorphous imatinib mesylate in highly pure form.
-
Page/Page column 3-4

(2008/12/08)

Process for the preparation of imatinib
The present invention provides process for the preparation of Imatinib and Imatinib salts, including processes that prepare intermediates for the production of Imatinib.
-
Page/Page column 7

(2008/06/13)

IMATINIB PRODUCTION PROCESS
Provided is a process for producing imatinib and salts thereof, e.g., imatinib mesylate. The process includes reacting4-(4-methyl-piperazin-1-ylmethyl)-benzoic acid with N-(5-amino-2-methylphenyl)-4-(3-pyridyl)-2-pyrimidine-amine in the presence of a carboxylic acid coupling reagent, to produce imatinib, and optionally converting the imatinib into a salt.
-
Page/Page column 7

(2008/12/08)

POLYMORPHIC FORMS OF IMATINIB MESYLATE AND PROCESSES FOR PREPARATION OF NOVEL CRYSTALLINE FORMS AS WELL AS AMORPHOUS AND FORM α
Solvates and crystalline forms of imatinib mesylate are described. Further, methods for preparing such solvates and crystalline forms of imatinib mesylate are described.
-
Page/Page column 56

(2010/11/29)

STABLE CRYSTAL FORM OF IMATINIB MESYLATE AND PROCESS FOR THE PREPARATION THEREOF
The invention relates to a stable, non hygroscopic alpha crystalline form of methane sulfonic acid addition salt of 4-(4-methyl piperazin-lyl methyl)-N-[4-methyl-3-(4-pyridin-3-yl) pyrimidin-2-yl amino) phenyl]-benzamide (imatinib mesylate). A process for
-
Page/Page column 10

(2008/06/13)

Imatinib mesylate alpha form and production process therefor
Provided is a process for preparing crystalline imatinib mesylate in substantially pure α-form, which preferably includes crystallizing imatinib mesylate from an organic solvent containing imatinib and methanesulfonic acid, and seed crystals of imatinib m
-
Page/Page column 4

(2008/06/13)

POLYMORPHIC FORMS OF IMATINIB MESYLATE
The present invention relates to novel crystalline polymorphic Form I and Form II of imatinib mesylate and methods for their preparation. The Form I is prepared by slurrying imatinib mesylate α2 or β polymorphic Form in chloroform and water wit
-
Page/Page column 13

(2008/06/13)

Process of preparing imatinib and imatinib prepared thereby
A process of preparing imatinib, either as the free base or as an acid addition salt, which process comprises reacting N-(2-methyl-5-aminophenyl-4-(3-pyridyl)-2-pyrimidine amine of formula (II) with a 4-(4-methyl-piperazino methyl)benzoyl halide of formula (III) in the presence of an inert organic solvent, so as to yield a hydrohalide salt of imatinib formula (I) where n represents 1, 2 or 3 and Hal represents bromo, chloro, fluoro or iodo, either in anhydrous or hydrated form, which can as desired optionally be further converted either to the free base or a further acid addition salt. The present invention is also concerned with imatinib prepared according to the above process.
-
Page/Page column 9-10

(2008/06/13)